Biogen and Samsung expand biosimilar deal to cover Lucentis, Eylea and China

After a successful partnership with its biosimilar joint venture Samsung Bioepis, Biogen has decided to expand into more drugs and China, too. Biogen is getting exclusive rights to Samsung Bioepis’ biosimilar versions of two blockbuster eye drugs, namely Roche and Novartis’ Lucentis and Regeneron and Bayer’s Eylea, covering the U.S., Europe, Japan and other key markets. The Big Biotech is also expanding its hold on three marketed anti-TNF copycats—Humira, Enbrel and Remicade biosimilars—to China.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001166 seconds